BBOT Key Statistics, Chart & Performance
The current stock price of BBOT is 13.19 USD. In the past month the price increased by 2.41%.
BBOT Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.29 | 388.96B | ||
| AMGN | AMGEN INC | 14.91 | 175.60B | ||
| GILD | GILEAD SCIENCES INC | 14.79 | 150.25B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.72 | 117.69B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.7 | 83.72B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 780.96 | 52.62B | ||
| INSM | INSMED INC | N/A | 37.53B | ||
| NTRA | NATERA INC | N/A | 32.34B | ||
| BIIB | BIOGEN INC | 11.21 | 27.52B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 22.94B | ||
| INCY | INCYTE CORP | 16.65 | 20.98B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.31 | 20.81B |
Related stock screener links
About BBOT
Company Profile
Bridgebio Oncology Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The company is headquartered in South San Francisco, California. The company went IPO on 2024-02-09. The firm is focused on advancing the pipeline of novel small molecule therapeutics targeting RAS and PI3Ka malignancies. Its pipeline of RAS-targeted oncology drug candidates includes BBO-8520, BBO-10203, and BBO-11818. BBO-8520 (NCT06343402) is a direct inhibitor of KRASG12C in both the ON and OFF states that is being evaluated both as monotherapy and in combination with pembrolizumab in the Phase 1 ONKORAS-101 trial for patients with KRASG12C mutant non-small cell lung cancer. BBO-10203 (NCT06625775) is an orally bioavailable small molecule that selectively and specifically blocks the physical interaction between RAS and PI3Ka, resulting in the inhibition of RAS-driven PI3Ka-AKT signaling in tumors without the risk of hyperglycemia. BBO-11818 (NCT06917079) is a panKRAS inhibitor targeting mutant KRAS in both the ON and OFF states with strong potency against KRASG12D and KRASG12V mutants.
Company Info
BRIDGEBIO ONCOLOGY THERAPEUT
256 E. Grand Avenue, Suite 104
South San Francisco CALIFORNIA US
Employees: 0
Phone: 18577020377
BRIDGEBIO ONCOLOGY THERAPEUT / BBOT FAQ
What does BBOT do?
Bridgebio Oncology Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The company is headquartered in South San Francisco, California. The company went IPO on 2024-02-09. The firm is focused on advancing the pipeline of novel small molecule therapeutics targeting RAS and PI3Ka malignancies. Its pipeline of RAS-targeted oncology drug candidates includes BBO-8520, BBO-10203, and BBO-11818. BBO-8520 (NCT06343402) is a direct inhibitor of KRASG12C in both the ON and OFF states that is being evaluated both as monotherapy and in combination with pembrolizumab in the Phase 1 ONKORAS-101 trial for patients with KRASG12C mutant non-small cell lung cancer. BBO-10203 (NCT06625775) is an orally bioavailable small molecule that selectively and specifically blocks the physical interaction between RAS and PI3Ka, resulting in the inhibition of RAS-driven PI3Ka-AKT signaling in tumors without the risk of hyperglycemia. BBO-11818 (NCT06917079) is a panKRAS inhibitor targeting mutant KRAS in both the ON and OFF states with strong potency against KRASG12D and KRASG12V mutants.
What is the stock price of BRIDGEBIO ONCOLOGY THERAPEUT today?
The current stock price of BBOT is 13.19 USD. The price decreased by -0.83% in the last trading session.
Does BRIDGEBIO ONCOLOGY THERAPEUT pay dividends?
BBOT does not pay a dividend.
What is the ChartMill rating of BRIDGEBIO ONCOLOGY THERAPEUT stock?
BBOT has a ChartMill Technical rating of 5 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
How is the market expecting BBOT stock to perform?
13 analysts have analysed BBOT and the average price target is 23.8 USD. This implies a price increase of 80.44% is expected in the next year compared to the current price of 13.19.
Can you provide the PE ratio for BBOT stock?
The PE ratio for BRIDGEBIO ONCOLOGY THERAPEUT (BBOT) is 65.95. This is based on the reported non-GAAP earnings per share of 0.2 and the current share price of 13.19 USD.
BBOT Technical Analysis
ChartMill assigns a technical rating of 5 / 10 to BBOT.
BBOT Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to BBOT. BBOT scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
BBOT Financial Highlights
Over the last trailing twelve months BBOT reported a non-GAAP Earnings per Share(EPS) of 0.2. The EPS increased by 17.4% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | 2.39% | ||
| ROE | 2.49% | ||
| Debt/Equity | 0 |
BBOT Forecast & Estimates
13 analysts have analysed BBOT and the average price target is 23.8 USD. This implies a price increase of 80.44% is expected in the next year compared to the current price of 13.19.